F. Suzuki, K. Ishiwata
Nov 1, 1998
Citations
0
Influential Citations
14
Citations
Journal
Drug Development Research
Abstract
During the past decade, many neuroreceptors in humans and other animals have been visualized in vivo by positron emission tomography (PET) with corresponding radioligands. Because adenosine is a neuromodulator, PET assessment of the adenosine receptor system offers us an opportunity to understand the neurotransmission system in general. The 11C‐labeled selective adenosine A1 antagonists KF15372 ([3‐propyl‐11C]8‐dicyclopropylmethyl‐1, 3‐dipropylxanthine) and a 11C‐methyl derivative [11C]KF26345 and selective adenosine A2A antagonist KF17837 ([7‐methyl‐11C]‐(E)‐8‐(3,4‐dimethoxystyryl)‐1,3‐dipropyl‐7‐methylxanthine) and KF18446 ([7‐methyl‐11C]‐(E)‐8‐3,4,5‐trimethoxystyryl)‐1,3,7‐trimethylxanthine were evaluated in vivo as potential PET ligands for mapping CNS adenosine A1 and A2A receptors.